 |
|
 |
Alzheimer's |
|
|
Emerging Alzheimer's Disease Therapeutics
Publication Date February 2004
Publisher Navigant Consulting
Product Type Report
Pages 213
ISBN Number not applicable
Product Code NAV001
|
|
|
Summary
The classes of therapeutics currently indicated for the treatment of Alzheimer's disease (AD) are used either to slow disease progression (e.g., acetyl cholinesterase inhibitors and NMDA/glutamate receptor antagonists) or to alleviate cognitive symptoms (e.g., carnitine acetyltransferase stimulatnts and nootropic agents). Psychotropic agents are also used (mostly off-label) to treat others symptoms associated with AD, including psychosis, depression, schizophrenia, and anxiety disorders. However, there is no cure for this devastating disease, and most available therapeutics are limited in their efficacy. In addition, the patient population is expected to grow substantially through 2009 as global life expectancy increases and as the U.S. Baby Boomers age. Therefore, many pharmaceutical companies have recognized the opportunity to provide improved therapeutics and to capture market share within this growing category. Fourteen emerging therapeutics are forecasted to enter this segment between 2004 and 2009.
|
Content
I. Executive Summary
A. Alzheimer’s Disease Therapeutics Report Findings
B. Scope
C. Alzheimer’s Disease Pathophysiology
D. Prevalence and Incidence
1. Worldwide
2. United States
3. Model Assumptions
E. Current Treatments
F. Products in Development Analysis Methodology I
G. Emerging Products Benchmarking Analysis
H. Ranking Overview of Emerging Therapeutics
I. Annual Worldwide Revenues (2004E to 2009E)
1. Segment by Class (2004E and 2009E)
2. Supplier Market Share (2004E and 2009E)
J. Testimonials to Changes in Alzheimer’s Disease Care
K. Trends, Challenges, and Strategic Options
II. Objectives and Methodology
A. Report Objectives and Scope
1. Objectives
2. Scope
B. Methodology
1. Alzheimer’s Disease – Prevalence and Incidence Models
2. Emerging Products Benchmarking
a. Assessment Criteria
b. Clinical Scoring and Rationale
c. Corporate Strength Scoring and Rationale
3. Data Collection
a. Primary Sources
i. Surveyed Physicians
ii. Representative Questions
b. Secondary Sources
4. Market Trends, Challenges, and Strategic Options
a. Overview
b. External Analysis
III. Medical Overview
A. Definition
B. Scientific Background
1. The Central Nervous System
2. Theories of Neuronal Cell Death
a. Excitotoxicity
b. Mitochondrial Dysfunction
c. Oxidative Stress
C. Pathophysiology and Symptoms
1. Pathophysiology
2. Symptoms
D. Causes / Risk factors
1. Familial Alzheimer’s Disease
2. Sporadic Alzheimer’s Disease
E. Diagnosis
F. Prevalence and Incidence
1. Worldwide
2. United States
3. Model Assumptions
IV. Current Treatments
A. Current Treatments
1. Acetyl Cholinesterase (AChE) Inhibitors
2. NMDA / Glutamate Receptor Antagonists
3. Carnitine Acetyltransferase Stimulants
4. Anti-oxidants
5. Nootropic Agents (Undefined Mechanism)
6. Psychotropic Agents
7. Off-Label Therapeutics
b.Agitation Suppressants
c.Anti-depressants
d.Monoamine Oxidase B (MAO-B inhibitors)
8. Alternative Medicine
9. Other Therapies
B. Physician Survey Results
1. Physician Breakdown
2. Disease and Treatment Timeline
3. Referral Process
4. First and Second Line Treatments
5. Prescription Drug Use
6. Expected Changes in Standard of Care
V. Emerging Therapeutics
A. Products in Development Analysis Methodology
B. Compounds in Phase III or Later
1. Emerging Products Benchmarking Analysis
2. Competitive Landscape
3. Ranking Overview of Emerging Therapeutics
4. Assessment of Therapeutics
5. Key Trial Data
6. Key Corporate Strength Data
C. Compounds in Phase II
D. Compounds in Phase I
E. Compounds in Pre-Clinical Development
VI. Alzheimer’s Disease Market
A. Annual Worldwide Revenues (2004E to 2009E)
B. Segment by Class (2004E and 2009E)
C. Supplier Market Share (2004E and 2009E)
D. Company Analysis
1. Axonyx, Inc.
2. Bristol-Myers Squibb
3. Cephalon, Inc.
4. Daiichi Pharmaceuticals
5. Eisai Co. Ltd.
6. Forest Laboratories, Inc.
7. Janssen Pharmaceutica (J&J)
8. Merck & Co.
9. Novartis
10. Pfizer
11. Sanofi-Synthelabo
12. Savient Pharmaceuticals, Inc.
13. Shire Pharmaceuticals Group, plc
14. Somerset Pharmaceuticals, Inc.
15. Teva Pharmaceutical Industries, Ltd.
16. Wyeth
E. Market Model Assumptions
VII. Trends, Challenges, and Strategic Options
A. Overview
B. Alzheimer’s Disease and Dementia Market Trends
1. Overview
2. Increased Patient and Family Initiative
3. Near Term Approval of Drugs With Novel Mechanisms
4. Approval of Additional Drugs to Treat Behavioral Symptoms
C. Alzheimer’s Disease and Dementia Market Challenges
1. Overview
2. Lack of Definitive Diagnostic Tests
3. Limited Efficacy of Alzheimer’s Disease Treatments
4. Disease Complexity
D. Strategic Options
1. Overview
2. Seek MCI Indication in Addition to AD
3. Develop Combination Therapies to Increase Market Share
4. Employ Robust Sales and Marketing Strategies
a. Marketing to Patients: Employing Branding Strategies and Targeting Baby Boomers
b. Selling to Physicians: Improve Sales Strategies
Appendix
A. Definitions
B. Acronyms
C. Companies
D. Market Model
|
|
|
